CWBR Key Statistics, Chart & Performance
The current stock price of CWBR is 0.761 USD. In the past month the price decreased by -62.33%. In the past year, price decreased by -56.01%.
CWBR Latest News, Press Relases and Analysis
CWBR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.61 | 410.78B | ||
| AMGN | AMGEN INC | 15.38 | 181.11B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.88B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 109.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 80.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 831.14 | 55.56B | ||
| INSM | INSMED INC | N/A | 42.83B | ||
| NTRA | NATERA INC | N/A | 32.64B | ||
| BIIB | BIOGEN INC | 10.62 | 26.07B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 21.35B | ||
| INCY | INCYTE CORP | 16.49 | 20.67B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About CWBR
Company Profile
CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
Company Info
COHBAR INC
1455 Adams Drive, Suite 2050
Menlo Park CALIFORNIA 94025 US
CEO: Steven Engle
Employees: 9
Phone: 16504467888
COHBAR INC / CWBR FAQ
What does CWBR do?
CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
What is the current price of CWBR stock?
The current stock price of CWBR is 0.761 USD. The price decreased by -15.44% in the last trading session.
Does COHBAR INC pay dividends?
CWBR does not pay a dividend.
What is the ChartMill rating of COHBAR INC stock?
CWBR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CWBR stock to perform?
6 analysts have analysed CWBR and the average price target is 18.36 USD. This implies a price increase of 2312.61% is expected in the next year compared to the current price of 0.761.
What is the ownership structure of COHBAR INC (CWBR)?
You can find the ownership structure of COHBAR INC (CWBR) on the Ownership tab.
CWBR Technical Analysis
CWBR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CWBR. The financial health of CWBR is average, but there are quite some concerns on its profitability.
CWBR Financial Highlights
Over the last trailing twelve months CWBR reported a non-GAAP Earnings per Share(EPS) of -4.36. The EPS increased by 8.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.44% | ||
| ROE | -133.58% | ||
| Debt/Equity | 0 |
CWBR Forecast & Estimates
6 analysts have analysed CWBR and the average price target is 18.36 USD. This implies a price increase of 2312.61% is expected in the next year compared to the current price of 0.761.